Trial Profile
A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of adding Symlin [pramlintide] to Lantus (insulin glargine) in subjects with type 2 diabetes who are not achieving glycemic targets
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2015
Price :
$35
*
At a glance
- Drugs Pramlintide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amylin Pharmaceuticals; AstraZeneca
- 08 Nov 2006 Status change
- 27 Jul 2006 New trial record.